Alton Shader was named Chief Executive Officer of Sotera Health Co, effective May 26, 2026. As of November 6, 2026, Sotera Health Co has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 5, 2026 to August 14, 2026, naming 3 appointments and 1 departure (Form 8-K, May 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Sotera Health Co? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Sotera Health Co reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-05 to 2026-08-14. They name 3 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Sotera Health Co files it.
Also on the record for Sotera Health Co
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.12% of the class | 5%+ stakes | Source |
| October 9, 2026 | Stake report, Schedule 13G/A, by Sachem Head Capital Management LP | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Sculptor Capital LP | 8.41% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Sessa Capital IM, L.P. | 9.5% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.4% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G, by Sachem Head Capital Management LP | 5.46% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by GTCR INVESTMENT XI LLC | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by WARBURG PINCUS & CO. | — | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 10, 2026 | Stake report, Schedule 13G/A, by GTCR INVESTMENT XI LLC | 11.2% of the class | 5%+ stakes | Source |
| March 10, 2026 | Stake report, Schedule 13G/A, by WARBURG PINCUS & CO. | 11.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Sessa Capital GP, LLC | 7.23% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sotera Health Co now and the warning signs.
Free to see. No signup.
Keep reading
More on Sotera Health Co and the records around it.
Sotera Health Co elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- GTCR INVESTMENT XI LLC also filed stake reports on 1 other company: Vivid Seats Inc. (Nov 2025)
- Sachem Head Capital Management LP also filed stake reports on 1 other company: Ionic Digital Inc. (Oct 2026)
- Sessa Capital (Master), L.P. also filed stake reports on 2 other companies: Fortrea Holdings Inc. (Feb 2026), Garrett Motion Inc. (Aug 2025)
Watch Sotera Health Co
Get an email when Sotera Health Co files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sotera Health Co?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sotera Health Co: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sotera Health Co covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 23 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-14 | Out | Director | 2026-08-13 | 8-K, 2026-08-14 | |
| 2026-05-05 | In | Chief Executive Officer | 2026-05-26 | 8-K, 2026-05-05 | |
| 2026-05-05 | In | Chairman of the Board | 8-K, 2026-05-05 | ||
| 2026-05-05 | In | Executive Chairman | 8-K, 2026-05-05 |
Who leads Sotera Health Co, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: James C. Neary, departure reported, effective 2026-08-13 (filed 2026-08-14). No successor is named in these filings.
- Chief Executive Officer: Alton Shader, appointed, effective 2026-05-26 (filed 2026-05-05).
- Executive Chairman: Michael B. Petras, appointed (filed 2026-05-05).
- Chairman of the Board: Michael B. Petras, appointed (filed 2026-05-05).
New leaders reset buying decisions — get the Full Report on Sotera Health Co: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Sotera Health Co, with the record behind each one.
Find candidates like Director at Sotera Health CoEvery change, in the filing's words
Departing: James C. Neary, Director, effective 2026-08-13
On August 11, 2026, James C. Neary notified the Board of Directors (the "Board") of Sotera Health Company (the "Company") of his resignation as a Class I director, effective August 13, 2026 (the "Effective Date").
- Mr. Neary's resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
- In connection with Mr. Neary's resignation, the Board fixed the size of the Board at eleven directors as of the Effective Date.
Appointed: Alton Shader, Chief Executive Officer, effective 2026-05-26
In accordance with the Company's executive succession plans, on May 5, 2026, the Company announced a leadership transition pursuant to which, on May 1, 2026, the Board of Directors (the "Board"), at the recommendation of the Nominating and Corporate Governance Committee, appointed Alton Shader to serve as Chief Executive Officer of the Company ("CEO") and a Class II director of the Board, effective as of May 26, 2026 (the "Effective Date").
Appointed: Michael B. Petras, Chairman of the Board
Michael B. Petras, Jr. will transition from his role as CEO of the Company and Chairman of the Board and, on May 1, 2026, the Board appointed Mr. Petras to serve as Executive Chairman of the Board ("Executive Chairman"), as of the Effective Date.
Appointed: Michael B. Petras, Executive Chairman
Pursuant to the MP Amendment, Mr. Petras will serve as Executive Chairman as described above, and will receive base salary at an annual rate of $900,000 and will be eligible to participate in the AIP with a target bonus opportunity equal to 110% of base salary.
- Mr. Petras will continue to serve as a Class I director of the Board and as an executive officer and employee of the Company.
- Mr. Shader, age 52, has served as Chief Executive Officer and a member of the board of directors of Viant Medical, LLC ("Viant"), a medical device manufacturing services company, since 2019.
- Prior to joining Viant, Mr. Shader held a number of senior leadership roles at Hill-Rom, including as President of Hill-Rom's global Front Line Care business, which included Welch Allyn.
- Mr. Shader previously held several senior positions at Baxter International Inc. in Europe and the United States, including as General Manager of its North America Renal business.
- Mr. Shader has more than 20 years of experience in global medical device leadership roles.
- Mr. Shader has a bachelor's degree in economics and psychology from Claremont McKenna College and an M.B.A. from Stanford University.
- Offer Letter with Mr. Shader In connection with Mr. Shader's appointment as CEO, the Company entered into an offer letter, dated May 1, 2026, with Mr. Shader (the "AS Offer Letter").
- Additionally, in the event of a termination of Mr. Shader's employment by the Company without Cause, any unvested Sign-On RSUs that would have vested during the two-year period immediately following the date of such termination will vest immediately upon such termination.
Tools for this story
Each opens in a new tab, filled in for Sotera Health Co. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.